The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

XP Power founder trims holding

Wed, 04th Aug 2010 16:28

XP Power deputy chairman James Peters raised £1.47m from a share disposal two days after bumper interim figures from the power control products supplier. Peters sold 200,000 shares at 735p each. Peters founded XP in 1988 and still owns nearly 2.7m shares, which is equivalent to 14%. That still makes him the biggest shareholder in XP. It was announced yesterday evening that finance director Mickey Lynch had sold 25,000 shares at 730.21p a share. That raised nearly £183,000 and left Lynch with 81,000 shares. Lynch bought 3,500 shares at 372p each and 2,500 shares at 362p each last November. That indicates how strong the XP share price has been in recent months. The share price is more than five times the level it was at the beginning of 2009. XP nearly doubled its pre-tax profit from £3.8m to £7.3m in the six months to June 2010. Revenues were 23% higher at £40.7m and they should continue to improve in the second half. XP Power has record order books.Edison Investment Research says that a higher proportion of own-designed/own-manufactured products has enabled XP to increase its margins. XP is using around 50% of its Chinese capacity and it is planning a factory in Vietnam, which should be in production before the end of 2011. Edison upgraded its 2010 earnings per share forecast by 13% to 62p. That means that the shares are trading on less than 12 times prospective earnings for 2010. Top Director BuysCapital & Counties Properties (CAPC) Director name: Mr Gary YardleyAmount purchased: 88,579 @ 112.05p Value: £99,253Capital & Counties Properties (CAPC) Director name: Mr Ian DurantAmount purchased: 64,024 @ 112.05p Value: £71,739Mid Wynd International Inv Trust (MWY) Director name: Mr Russell Napier Amount purchased: 5,200 @ 960.00p Value: £49,920Filtronic (FTC) Director name: Mr Edwin Graham MeekAmount purchased: 50,000 @ 38.00p Value: £19,000Filtronic (FTC) Director name: Mr Howard FordAmount purchased: 42,204 @ 35.00p Value: £14,771Summit Corporation (SUMM) Director name: Mr Raymond SpencerAmount purchased: 400,000 @ 2.93p Value: £11,720Severn Trent (SVT) Director name: Mr Gordon FryettAmount purchased: 1,000 @ 1,141.00p Value: £11,410Top Director SellsXP Power (XPP) Director name: Mr James E PetersAmount sold: 200,000 @ 735.00p Value: £1,470,000BT Group (BT.A) Director name: Mr Ian LivingstonAmount sold: 72,725 @ 141.99p Value: £103,262BT Group (BT.A) Director name: Mr Tony ChanmugamAmount sold: 19,635 @ 141.99p Value: £27,880
More News
24 Feb 2020 10:52

Summit Therapeutics Delists In London As Focus Shifts To US

Summit Therapeutics Delists In London As Focus Shifts To US

Read more
24 Jan 2020 12:49

Summit Therapeutics Chief Operating & Medical Officer Roblin Resigns

Summit Therapeutics Chief Operating & Medical Officer Roblin Resigns

Read more
23 Jan 2020 16:47

Summit Gets More Funding For C. Difficile Infection Treatment

Summit Gets More Funding For C. Difficile Infection Treatment

Read more
24 Dec 2019 10:27

Summit Therapeutics Shuffles Board After Raising USD50 Million

Summit Therapeutics Shuffles Board After Raising USD50 Million

Read more
24 Dec 2019 09:09

Summit Therapeutics raises $40m, completes board restructuring

(Sharecast News) - Antibiotic innovation company Summit Therapeutics raised $50.0m on Tuesday by way of a subscription and placing of new ordinary shares and warrants.

Read more
17 Dec 2019 13:20

Summit Therapeutics Reports Decrease In Revenue In Third Quarter

Summit Therapeutics Reports Decrease In Revenue In Third Quarter

Read more
6 Dec 2019 13:34

Summit Therapeutics Plans Wholesale Changes As It Raises Cash

Summit Therapeutics Plans Wholesale Changes As It Raises Cash

Read more
6 Dec 2019 08:56

Summit Therapeutics raising $50m, plans to delist from AIM

(Sharecast News) - Antibiotic innovation company Summit Therapeutics announced a proposed fundraising of about $50m through a subscription and placing of new ordinary shares and warrants to existing investors on Friday, which would be subject to certain shareholder approvals being obtained and certain customary closing conditions being satisfied.

Read more
11 Oct 2019 12:53

Summit Therapeutics Sinks To Interim Loss On Ezutromid Discontinuation

Summit Therapeutics Sinks To Interim Loss On Ezutromid Discontinuation

Read more
7 Oct 2019 13:23

Summit Therapeutics Posts Explanation For Ridinilazole Trial In C Diff

Summit Therapeutics Posts Explanation For Ridinilazole Trial In C Diff

Read more
3 Oct 2019 14:23

Summit Therapeutics Reports Positive Ridinilazole Trial Results

Summit Therapeutics Reports Positive Ridinilazole Trial Results

Read more
17 Jul 2019 13:48

Summit Therapeutics New Antibiotic Shows Potential Against Gonorrhoea

(Alliance News) - Summit Therapeutics PLC on Wednesday highlighted the potential of its preclinical new class antibiotic, SMT-571, to treat gonorrhoea, at the STI & HIV World Congress in said

Read more
12 Jun 2019 13:54

Summit Therapeutics Narrows First Quarter Loss As Expenses Drop

(Alliance News) - Summit Therapeutics on Wednesday said its loss narrowed in its financial first quarter due to an increase in other operating income and a reduction in operating which develops a

Read more
15 Apr 2019 11:26

Summit Therapeutics DDS-04 Series Antibiotic Cures Infection In Study

LONDON (Alliance News) - Summit Therapeutics PLC on Monday presented proof of concept data for its DDS-04 series of antibiotics targeting Enterobacteriaceae, a family of bacteria that cause severe

Read more
15 Apr 2019 10:16

Summit Therapeutics upbeat on latest DDS-04 data

(Sharecast News) - Antibiotic innovation firm Summit Therapeutics reported on in vivo proof-of-concept data for the DDS-04 series of new mechanism antibiotics targeting enterobacteriaceae on Monday, having presented them at the 29th European Congress of Clinical Microbiology and Infectious Diseases in Amsterdam.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.